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Abstract
Introduction: In October 2015, the Food and Drug Administration (FDA) instituted an update to the
mandatory Risk Evaluation and Mitigation Strategy (REMS) program for clozapine to improve safety
monitoring of hematologic events. However, the impact of the clozapine REMS program on reporting of
hematologic adverse events has not been quantified.
Methods: We assessed adverse event reports for agranulocytosis, granulocytopenia, leukopenia, and
neutropenia from the FDA Adverse Event Reporting System (FAERS) for a 1-year time period before
(October 2014 to September 2015, pre-REMS) and after (October 2015 to September 2016, post-REMS) the
implementation of the clozapine REMS program. The AERSMine platform was used to capture historical
effect estimates (October 2004 to September 2014). Reporting odds ratios (ROR), proportional reporting
ratios (PRR), and corresponding Taylor series 95% confidence intervals (CIs) were calculated for hematologic
events with clozapine compared with all other medications using OpenEpi.
Results: Reporting rates for agranulocytosis, granulocytopenia, leukopenia, and neutropenia with clozapine
all increased from the pre-REMS to post-REMS time frames, ranging from a 2-fold increase with leukopenia
to a 40-fold increase with neutropenia; the composite measure of all hematologic reports had a 12-fold
increase. During the post-REMS time frame, the ROR increased by 1691% (111.4, 95% CI 100.6-123.4)
compared with the pre-REMS time frame (7.1, 95% CI 5.2-9.6), and the PRR increased by 1280% (83.1, 95%
CI 76.8-90.0 vs 6.9, 95% CI 5.1-9.4) for the composite outcome.
Discussion: We observed significant increases in reports of hematologic adverse events with clozapine after
the introduction of the clozapine REMS program. Future research should explore the impact of the less
stringent exclusionary and discontinuation criteria on utilization (eg, expanded access) and clinical outcomes
(eg, treatment effectiveness and adverse events).
Keywords: clozapine, neutropenia, pharmacovigilance, drug safety, agranulocytosis, granulocytopenia,
leukopenia, Risk Evaluation and Mitigation Strategy Program
1 PhD Student in Health Outcomes Research, University of Rhode Island
College of Pharmacy, Kingston, Rhode Island, ORCID: https://orcid.org/
0000-0002-9941-9893; 2 Recent PharmD Graduate, University of Rhode
Island College of Pharmacy, Kingston, Rhode Island, ORCID: https://orcid.
org/0000-0001-8181-5209; 3 (Corresponding author) Associate Professor
in Health Outcomes, University of Rhode Island College of Pharmacy,
Kingston, Rhode Island; Director of Outcomes Research, Veterans Affairs
Medical Center, Infectious Diseases Research Program and Center of
Innovation in Long Term Services and Supports, Providence, Rhode
Island; Adjunct Assistant Professor of Health Services, Policy and
Practice, Brown University School of Public Health, Providence, Rhode
Island, Aisling_Caffrey@uri.edu, ORCID: https://orcid.org/0000-0002-
4180-027X
Disclosures: A.R.C. received research funding from Pfizer, Merck (Cubist),
and The Medicines Company. There are no other conflicts or funding to
disclose.
Q 2020 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. This is an
open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which








hc_2020_05_070.pdf by guest on 21 July 2020
Introduction
Clozapine is an atypical antipsychotic medication first
approved in the United States in 1989. US Food and Drug
Administration (FDA) approved indications include treat-
ment-resistant schizophrenia as well as suicidal behavior
in schizophrenia or schizoaffective disorder.1 Clozapine
has been shown to be 1 of the most effective treatment
options available for these 2 indications and is recom-
mended as a potential first-line treatment option.2-4 Even
with clozapine’s documented effectiveness, it is consid-
ered to be underutilized, in part due to its severe side
effect profile.5 Clozapine has several black box warnings
regarding potential severe adverse drug reactions (ADRs),
including hematologic abnormalities.1 Although the label
specifically mentions neutropenia, there are 3 additional
hematologic abnormalities that are clinically similar but
have different defining parameters: agranulocytosis,
granulocytopenia, and leukopenia. Agranulocytosis is
defined as having an absolute neutrophil count (ANC)
below 500/lL.6 Granulocytopenia is defined as an ANC
between 500/lL and 1000/lL.7 Leukopenia is defined as
have a total white blood cell (WBC) count of less than
4000/lL.8 Neutropenia is defined as having an ANC below
1500/lL.9
The mechanism of action that causes these hematologic
changes is unknown and has not been shown to be dose
dependent.1 Risk of these reactions is greatest during the
first 18 weeks of therapy with subsequent decreases in risk
thereafter.1 With the body’s inability to properly protect
against pathogens, this can result in increased risk of
infections.10 Further, as the duration of these hematologic
reactions increases, the risk of infection increases, and
therefore, clinically managing these decreased WBC
counts becomes more difficult.10 In the event of
hematologic abnormalities necessitating clozapine discon-
tinuation, it has been reported that discontinuation may
be associated with worsening psychiatric symptoms,
reduced quality of life, and increased risk of suicide.11-13
In October 2015, the mandatory FDA Risk Evaluation and
Mitigation Strategy (REMS) program for clozapine was
modified to improve safety monitoring in patients treated
with clozapine. A REMS program is a risk management
program that mandates safety monitoring activities that
may prevent occurrence of the event, reduce severity, or
identify the adverse event sooner.14 The clozapine REMS
program replaced the 6 existing prescribing registries that
were maintained by individual manufacturers of cloza-
pine.15 The modified REMS program is shared by
prescribers, pharmacies, and patients in 1 centralized
program. Both prescribers and pharmacies must be
certified in the program in order to prescribe and dispense
clozapine, respectively. A requirement of the clozapine
REMS program is the monitoring of ANC before each
prescription of clozapine can be dispensed.15 Some
additional components of this modified REMS program
include lowering the discontinuation threshold from an
ANC of less than 1500/lL to an ANC of less than 1000/lL
as well as allowing patients with benign ethnic neutrope-
nia to be treated with clozapine (Table 1). The purpose of
initiating this new mandatory REMS program was ‘‘to
address continuing safety concerns and current knowl-
edge about a serious blood condition called severe
neutropenia.’’15(p1) The impact of the REMS program on
addressing safety concerns with neutropenia is not well
defined. Therefore, the objective of our study was to
assess adverse event reporting rates of hematologic
events with clozapine before and after the implementa-
tion of the clozapine REMS program.
Methods
We reviewed reports submitted to the FDA’s Adverse
Event Reporting System (FAERS) for a 1-year time period
before (October 2014 through September 2015, pre-
REMS) and after (October 2015 through September
2016, post-REMS) the implementation of the clozapine
REMS program.16 We only included initial reports and
excluded reports missing all 3 of the following: event date,
sex, and age. The AERSMine platform was also analyzed
for the time period of October 2004 through September
2014 to capture historical effect estimates.17 We identified
reactions from adverse event reports using the MedRA
terms (medical dictionary for regulatory activities) agran-
ulocytosis, granulocytopenia, leukopenia, neutropenia, and
neutropenic, and subsequent listings of adverse events
were reviewed for inclusion. Reports were assessed for
mention of either the brand names Clozaril, Fazaclo,
Leponex, and Versacloz or the generic drug name
clozapine. The reporting odds ratio (ROR), proportional
reporting ratio (PRR),18 and corresponding Taylor series
95% confidence intervals (CIs) were calculated using
OpenEpi19 for all 3 time frames comparing clozapine
hematologic reports with all other medications. Although
the FDA label broadly refers to these hematologic
reactions as neutropenia, we assessed agranulocytosis,
granulocytopenia, leukopenia, and neutropenia individu-
ally and also as a composite reaction.
Results
During the 1-year pre-REMS time frame, there were
765 185 total adverse event reports, and clozapine was
listed in 0.27% of these reports (n¼2048; Table 2). In the
1-year post-REMS time frame, there were 881 184 total
adverse event reports with clozapine comprising 0.26% of
reports (n¼2248). In the 11-year historical time frame
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prior to REMS, there were 5 828 458 total adverse event
reports, and 0.76% included clozapine (n¼44 164).
During the pre-REMS time frame, the ROR for agranulo-
cytosis with clozapine was 29.3 (95% CI 19.1-44.8) and a
PRR of 29.0 (95% CI 19.0-44.2), which were similar to the
historical time frame (ROR 23.2, 95% CI 21.6-24.8; PRR
22.7, 95% CI 21.2-24.3; Table 3). During the post-REMS
time frame, the ROR increased by 397% (116.2, 95% CI
93.0-145.2) compared with the pre-REMS time frame, and
the PRR increased by 382% (110.9, 95% CI 89.5-137.5).
For granulocytopenia, the pre-REMS ROR was 168.4 (95%
CI 76.6-370.3), and the PRR was 167.7 (95% CI 76.5-367.8),
which were 1.7 times lower than the historical reporting
rates (ROR 292.7, 95% CI 272.2-314.7; PRR 277.4, 95% CI
258.3-297.9). During the post-REMS time frame, there was
more than a 13.4-fold increase in the ROR (2261.3, 95% CI
1546.0-3306.0) and a 12.5-fold increase in the PRR
(2089.3, 95% CI 1436.0-3041.0) compared with the pre-
REMS reporting rates.
The pre-REMS reporting rates for leukopenia with
clozapine were almost 3 times lower with an ROR of 4.5
(95% CI 1.7-12.0) and a PRR of 4.5 (95% CI 1.7-12.0) than
the historical reporting rates (ROR 13.6, 95% CI 13.0-14.3;
PRR 13.1, 95% CI 12.5-13.8). The post-REMS reporting
rates were more than double those of the pre-REMS time
frame but slightly lower than the historical reporting rates
with an ROR of 10.3 (95% CI 5.1-20.9) and a PRR of 10.3
(95% CI 5.1-20.7).
The pre-REMS and historical reporting rates for neutro-
penia with clozapine were lower than with the other
reactions (pre-REMS ROR 1.4, 95% CI 0.6-3.1; PRR 1.4,
95% CI 0.6-3.1; historical ROR 10.8, 95% CI 10.5-11.2; PRR
9.8, 95% CI 9.5-10.1). During the post-REMS time frame,
there was a 41-fold increase in reporting rates compared
with the pre-REMS time frames with an ROR of 65.6 (95%
CI 57.6-74.8) and a PRR of 57.2 (95% CI 51.0-64.2).
The composite measure of all hematologic reactions with
clozapine produced a historical estimate with an ROR of
TABLE 1: Changes in the clozapine Risk Evaluation and Mitigation Strategy (REMS) program (October 2015)15
Pre-REMSa Post-REMSa
WBC count monitoring Dose discontinuation recommended if WBC ,3000 No WBC count monitoring
ANC Dose discontinuation recommended if ANC ,1500 Dose discontinuation recommended if ANC ,1000
NNRMF Patients were listed in the NNRMF if they had
WBC ,2000 or ANC ,1000
The NNRMF was discontinued
Patients with BEN Patients are not able to receive treatment Patients are able to receive treatment; dose
discontinuation recommended if ANC ,500
Rechallenge Not allowed if WBC ,2000 or ANC ,1000 Is not recommended, but prescribers are allowed to
if they determine the benefit outweighs the risk
ANC¼ absolute neutrophil count; BEN¼ benign ethnic neutropenia; NNRMF¼ national non-rechallenge master file; WBC¼white blood cell.
aUnits in cells/lL.







Total reactions 5 828 458 765 185 881 184
Total clozapine reactions 44 168 2048 2248
Total agranulocytosis reactions 6468 319 466
Clozapine agranuloytosis reactions 955 23 103
Total granulocytopenia reactions 3408 29 203
Clozapine granulocytopenia reactions 2315 9 171
Total leukopenia reactions 19 641 337 312
Clozapine leukopenia reactions 1787 4 8
Total neutropenia reactions 68 722 1615 2304
Clozapine neutropenia reactions 4772 6 294
Total hematologic reactions 98 239 2300 3285
Clozapine hematologic reactions 9829 42 576
REMS¼ Risk Evaluation and Mitigation Strategy.








hc_2020_05_070.pdf by guest on 21 July 2020
18.4 (95% CI 18.0-18.9) and a PRR of 14.6 (95% CI 14.3-
14.8) and a pre-REMS ROR of 7.1 (95% CI 5.2-9.6) and a
PRR of 6.9 (95% CI 5.1-9.4). During the post-REMS time
frame, the ROR increased by 1569% (111.4, 95% CI 100.6-
123.4) compared with the pre-REMS time frame, and the
PRR increased by 1204% (83.1, 95% CI 76.8-90.0).
Three of the adverse reactions assessed had statistically
significant increases in effect estimates of at least a 4-fold
increase and nonoverlapping confidence intervals from
the historical time frame to the post-REMS time frame
although leukopenia had a decrease. Neutropenia had the
largest increase from the pre-REMS to the post-REMS
time frame with a greater than 40-fold increase in the
measures of association (ROR: 65.6; PRR: 57.2 vs ROR:
1.4; PRR: 1.4). The composite measure of all hematologic
reactions had greater than a 5-fold increase in the post-
REMS study period compared with the historical period
and greater than a 12-fold increase compared with the 1-
year pre-REMS period.
Discussion
To our knowledge, ours is the first study to assess
hematologic adverse event reports with clozapine follow-
ing the implementation of the clozapine REMS program.
Our study showed significant increases in reports of
hematologic adverse events with clozapine after the
introduction of the clozapine REMS program. Reporting
rates for agranulocytosis, granulocytopenia, leukopenia,
and neutropenia with clozapine all increased from the pre-
REMS to post-REMS time frames, ranging from a 2-fold
increase with leukopenia to a 40-fold increase with
neutropenia, and the composite measure of all hemato-
logic reports had a 12-fold increase.
Conversion to a centralized clozapine REMS program now
allows pharmacies and prescribers to monitor patients
within a single, centralized system, eliminating reporting
burden and potential confusion and discrepancies when
there were 6 separate registries. There are several possible
explanations for the significant increase in reporting rates
of these adverse reactions since implementation of the
revised REMS program, including changes in exclusionary
criteria, monitoring parameters, and renewed attention to
safety monitoring with clozapine. For example, under to
the clozapine REMS program, providers are instructed to
report clozapine-related adverse events directly to the
Clozapine REMS Program Contact Center. Providers are
also encouraged to submit an adverse event report to the
FDA MedWatch Reporting System. Therefore, submission
of adverse event reports to the Clozapine REMS Program
Contact Center may increase voluntary reporting to the
FDA MedWatch Reporting System.
The clozapine REMS program requires monitoring for
neutropenia only by ANC before each prescription
dispensing, whereas previously it was monitored by ANC
in conjunction with WBC count (Table 1).15 Although the
frequency of this monitoring has remained the same, the
clozapine REMS program amended the discontinuation
threshold for patients from an ANC of less than 1500/lL to
an ANC of less than 1000/lL. Another update is that
patients who have benign ethnic neutropenia are now
able to be treated with clozapine although they were not
eligible prior to the modified REMS program. Another
change is that prescribers are allowed to rechallenge
patients if they believe the benefits outweigh the risks,
whereas previously, patients with either a WBC count of
less than 2000/lL or ANC less than 1000/lL were placed
on the National Non-Rechallenge Master File list and were
not allowed to rechallenge.
Clozapine is an effective treatment option and may be 1 of
the last options available for patients who have failed
previous therapies. Under the clozapine REMS program,
less stringent parameters for exclusion, discontinuation,
and rechallenge (Table 1) may have expanded access to
clozapine. One study20 conducted in a single state
psychiatric hospital found that clozapine prescribing had
a nonsignificant increase in the 6 months following the
REMS implementation. As such, our findings of increased
hematologic adverse event reporting with clozapine after
TABLE 3: Risk estimates with corresponding 95% confidence intervals for hematologic adverse reactions with clozapine in
the Food and Drug Administration Adverse Event Reporting System
Historical: Oct 2004 to Sept 2014 Pre-REMS: Oct 2014 to Sept 2015 Post-REMS: Oct 2015 to Sept 2016
ROR PRR ROR PRR ROR PRR
Agranulocytosis 23.2 (21.6-24.8) 22.7 (21.2-24.3) 29.3 (19.1-44.8) 29.0 (19.0-44.2) 116.2 (93.0-145.2) 110.9 (89.5-137.5)
Granulocytopenia 292.7 (272.2-314.7) 277.4 (258.3-297.9) 168.4 (76.6-370.3) 167.7 (76.5-367.8) 2261.3 (1546.0-3306.0) 2089.3 (1436.0-3041.0)
Leukopenia 13.6 (13.0-14.3) 13.1 (12.5-13.8) 4.5 (1.7-12.0) 4.5 (1.7-12.0) 10.3 (5.1-20.9) 10.3 (5.1-20.7)
Neutropenia 10.8 (10.5-11.2) 9.8 (9.5-10.1) 1.4 (0.6-3.1) 1.4 (0.6-3.1) 65.6 (57.6-74.8) 57.2 (51.0-64.2)
Composite 18.4 (18.0-18.9) 14.6 (14.3-14.8) 7.1 (5.2-9.6( 6.9 (5.1-9.4) 111.4 (100.6-123.4) 83.1 (76.8-90.0)
PRR¼ proportional reporting ratio; REMS¼ Risk Evaluation and Mitigation Strategy; ROR¼ reporting odds ratio.
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the introduction of the clozapine REMS program may be
due to increased utilization of clozapine.
In regards to the change in ANC level from pre-REMS to
post-REMS, patients may now continue clozapine treat-
ment when neutropenic as the discontinuation threshold
was lowered to the level of granulocytopenia. The
observed increases in granulocytopenia and agranulocy-
tosis may be due, in part, to additional patients reaching
these ANC parameters in the absence of discontinuation
at the detection of neutropenia, resulting in progression to
lower ANC levels. Another potential explanation for this
increase could be the notoriety effect, which is an increase
in reporting due to an ADR being highlighted in the
literature or media.21 With the introduction of the REMS
program, prescribers and patients may have become more
aware of these potential ADRs and more likely to report
them to the FAERS database when they occurred.
However, notoriety effects tend to wane over time, and
increases in reporting may have leveled off in recent
years.
The historical and pre-REMS reporting rates from our
study were similar to others in the literature. A
population-based case control study22 conducted in Hong
Kong reported a crude odds ratio of 36.0 (95% CI 4.6-
284.2) for agranulocytosis with clozapine from January
2004 through December 2013. Another case control
study,23 conducted in Berlin from 2000 through 2010,
reported an odds ratio of 49.7 (95% CI 6.0-999.0) for
agranulocytosis with clozapine after adjusting for age and
sex. As these case-control studies were small, the CIs were
wide. However, the effect estimated indicates a large,
statically significant increased risk of agranulocytosis with
clozapine as we observed in our study.
The FDA has made further modifications to the clozapine
REMS program. As part of this update, which took effect
February 28, 2019, prescribers are not required to be
certified in the REMS program in order to prescribe
clozapine in the inpatient setting as long as the patient is
already enrolled in the program.24 In addition, pharmacies
are no longer allowed to enroll patients in the clozapine
REMS program, and only the prescriber or the prescriber’s
designee may enroll patients.24 It is unclear how these
changes to the program have affected adverse event
reporting and is an area of further evaluation.
There were several limitations to our study in addition to
the notoriety effect listed previously. First and foremost,
neither incidence nor prevalence of either the exposure
(clozapine) or the outcome (hematologic events) can be
quantified from the FAERS database.25-27 In addition,
causality does not need to be established between the
medication and ADR in order for it to be reported and
documented in FAERS.27 Underreporting of known ADRs
is also a limitation of FAERS.28 Another potential
limitation is that the initial rollout of the REMS program
resulted in technical issues that led to implementation
complications for both prescribers and pharmacies.29 This
may have resulted in restricted access for patients who
were eligible for clozapine therapy.
The centralized clozapine REMS program enhances
tracking of patients and their laboratory values for all
health care providers involved in an effort to improve
patient outcomes. There was greater than a 2-fold
increase in risk estimates for agranulocytosis, granulocy-
topenia, leukopenia, and neutropenia with the composite
measure having a 12-fold increase after REMS introduc-
tion compared to the previous year’s reporting rates.
Although more hematologic events are being reported
since the modified clozapine REMS program was initiated,
it remains unclear how this REMS program may be
impacting clinical outcomes in patients. With new
requirements being added to the REMS program in
February 2019, future research should evaluate the effect
of the clozapine REMS program, including access and
utilization as well as positive clinical outcomes, such as
treatment effectiveness and early detection of safety
events, and negative clinical outcomes, such as increased
incidence of serious hematologic reactions and progres-
sion to more severe hematologic conditions.
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